Literature DB >> 20619346

Tumorigenic and adhesive properties of heparanase.

Flonia Levy-Adam1, Neta Ilan, Israel Vlodavsky.   

Abstract

Heparanase is an endo-β-glucuronidase that cleaves heparan sulfate side chains presumably at sites of low sulfation, activity that is strongly implicated with cell invasion associated with cancer metastasis, a consequence of structural modification that loosens the extracellular matrix barrier. In addition, heparanase exerts pro-adhesive properties, mediated by clustering of membrane heparan sulfate proteoglycans (i.e., syndecans) and activation of signaling molecules such as Akt, Src, EGFR, and Rac in a heparan sulfate-dependent and -independent manner. Activation of signaling cascades by enzymatically inactive heparanase and by a peptide corresponding to its substrate binding domain not only increases cell adhesion but also facilitates cancer cell growth. This notion is supported by preclinical and clinical settings, encouraging the development of anti-heparanase therapeutics. Here, we summarize recent progress in heparanase research emphasizing the molecular mechanisms that govern its pro-tumorigenic and pro-adhesive properties. Pro-adhesive properties of the heparanase homolog, heparanase 2 (Hpa2), are also discussed. Enzymatic activity-independent function of proteases (i.e., matrix metalloproteinases) is discussed in the context of cell adhesion and tumor progression. Collectively, these examples suggest that enzyme function exceeds beyond the enzymatic aspect, thus significantly expanding the scope of the functional proteome. Cross-talk with matrix metalloproteinases and the role of heparanase in pathological settings other than cancer are also described.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619346      PMCID: PMC2941534          DOI: 10.1016/j.semcancer.2010.06.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  106 in total

Review 1.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

2.  Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.

Authors:  Flonia Levy-Adam; Ghada Abboud-Jarrous; Marco Guerrini; Daniela Beccati; Israel Vlodavsky; Neta Ilan
Journal:  J Biol Chem       Date:  2005-03-10       Impact factor: 5.157

Review 3.  Matrix metalloproteinases: regulators of the tumor microenvironment.

Authors:  Kai Kessenbrock; Vicki Plaks; Zena Werb
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

4.  Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.

Authors:  Javier Redondo-Muñoz; Estefanía Ugarte-Berzal; María José Terol; Philippe E Van den Steen; Mercedes Hernández del Cerro; Martin Roderfeld; Elke Roeb; Ghislain Opdenakker; José A García-Marco; Angeles García-Pardo
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

5.  Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.

Authors:  P Bashkin; S Doctrow; M Klagsbrun; C M Svahn; J Folkman; I Vlodavsky
Journal:  Biochemistry       Date:  1989-02-21       Impact factor: 3.162

6.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

Review 7.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 8.  Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?

Authors:  I Vlodavsky; R Bar-Shavit; R Ishai-Michaeli; P Bashkin; Z Fuks
Journal:  Trends Biochem Sci       Date:  1991-07       Impact factor: 13.807

Review 9.  The role of heparanase in diseases of the glomeruli.

Authors:  Maciej Szymczak; Jakub Kuźniar; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-01-05       Impact factor: 4.291

10.  Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH.

Authors:  D Gilat; R Hershkoviz; I Goldkorn; L Cahalon; G Korner; I Vlodavsky; O Lider
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  31 in total

1.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

2.  Conformational changes of 1-4-glucopyranosyl residues of a sulfated C-C linked hexasaccharide.

Authors:  Alessia Coletti; Stefano Elli; Eleonora Macchi; Patrizia Galzerano; Leila Zamani; Marco Guerrini; Giangiacomo Torri; Elena Vismara
Journal:  Carbohydr Res       Date:  2014-02-25       Impact factor: 2.104

3.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

4.  Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.

Authors:  Miry Blich; Amnon Golan; Gil Arvatz; Anat Sebbag; Itay Shafat; Edmond Sabo; Victoria Cohen-Kaplan; Sirouch Petcherski; Shani Avniel-Polak; Amnon Eitan; Haim Hammerman; Doron Aronson; Elena Axelman; Neta Ilan; Gabriel Nussbaum; Israel Vlodavsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

Review 5.  Anti-tumor activities of matrine and oxymatrine: literature review.

Authors:  Yan Liu; Yang Xu; Weidan Ji; Xiaoya Li; Bin Sun; Quangen Gao; Changqing Su
Journal:  Tumour Biol       Date:  2014-02-14

Review 6.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

Review 7.  Genetics of human congenital urinary bladder disease.

Authors:  Adrian S Woolf; Helen M Stuart; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

8.  A new approach to glycan targeting: enzyme inhibition by oligosaccharide metalloshielding.

Authors:  John B Mangrum; Brigitte J Engelmann; Erica J Peterson; John J Ryan; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chem Commun (Camb)       Date:  2014-04-21       Impact factor: 6.222

9.  Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.

Authors:  Anurag Purushothaman; Stephen K Babitz; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

10.  Over-expression of human endosulfatase-1 exacerbates cadmium-induced injury to transformed human lung cells in vitro.

Authors:  Huiying Zhang; Donna R Newman; James C Bonner; Philip L Sannes
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-19       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.